Proprietary ²¹²Pb production technology provides access to an unmatched supply of alpha isotopes to accelerate clinical development of a portfolio of targeted alpha therapies.

AdvanCell is a radiopharmaceutical company that works with technology to develop a revolutionary cancer treatment called Targeted Alpha Therapy, providing new hope for …

AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of ²¹²Pb-ADVC001 in Metastatic Prostate Cancer

When highly energetic alpha particles pass through a cancer cell they deliver enormous damage. Targeted Alpha Therapy harnesses the power of alpha particles by attaching alpha emitting …

AdvanCell operates a comprehensive partnership program for taking novel Targeted Alpha Therapies from the lab through to Phase I and beyond. cGMP ISOTOPE AdvanCell provides …

These facilities produce stable and radioactive isotopes in short supply using reactors, accelerators, and other methods. ‍ The DOE IP supports the production and the development …

This website (Website) has been prepared by Advancell Isotopes Pty Ltd (ABN 42 633 959 010) (Advancell, we or our). Advancell maintains this Website to provide you and the general public …

Advancell Isotopes Pty Ltd (ABN 42 633 959 010) (Advancell, we or our) recognises the importance of protecting the privacy and the rights of individuals in relation to their personal …

We use cookies to help improve your experience of our website. This cookie policy is part of Advancell's privacy policy. It covers the use of cookies between your device and our site. Last …

This acceptable use policy covers the products, services, and technologies (collectively referred to as the “Products”) provided by Advancell under any ongoing agreement.